Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other Accumulated Expenses: 2019-2024

Historic Other Accumulated Expenses for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $17.8 million.

  • Kymera Therapeutics' Other Accumulated Expenses rose 15.41% to $14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.6 million, marking a year-over-year increase of 15.41%. This contributed to the annual value of $17.8 million for FY2024, which is 17.90% up from last year.
  • Per Kymera Therapeutics' latest filing, its Other Accumulated Expenses stood at $17.8 million for FY2024, which was up 17.90% from $15.1 million recorded in FY2023.
  • Kymera Therapeutics' 5-year Other Accumulated Expenses high stood at $17.8 million for FY2024, and its period low was $5.8 million during FY2020.
  • In the last 3 years, Kymera Therapeutics' Other Accumulated Expenses had a median value of $17.0 million in 2022 and averaged $16.6 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first spiked by 160.59% in 2021, then fell by 11.05% in 2023.
  • Over the past 5 years, Kymera Therapeutics' Other Accumulated Expenses (Yearly) stood at $5.8 million in 2020, then skyrocketed by 160.59% to $15.2 million in 2021, then rose by 11.91% to $17.0 million in 2022, then fell by 11.05% to $15.1 million in 2023, then increased by 17.90% to $17.8 million in 2024.